Brain tumors account for more than 15% of childhood cancers and are the second most common childhood cancer [1]. Despite significant advances in medical imaging and treatment monitoring, researchers and clinicians continue to face challenges when evaluating therapy response and tracking disease progression in pediatric oncology.
During Brain Tumor Awareness Month, Mint Medical is highlighting the role that standardized imaging assessments and structured data can play in supporting childhood cancer research.
Modern imaging technologies have improved the way therapy response and post-treatment changes are assessed. However, generating consistent, reproducible, and research-ready data remains a challenge across many studies and institutions.
To support these efforts, Mint Medical is proud to offer a portfolio of specialized radiology and clinical data response evaluation templates designed for pediatric oncology. These templates support the assessment of conventional therapies, immunotherapies, and emerging treatment approaches across a wide range of childhood cancers.
The mint Lesion platform provides structured reporting and standardized evaluation workflows for indications including High-Grade Glioma, Low-Grade Glioma, Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Sarcomas, and other solid tumors.
What sets mint Lesion apart is its versatility. Beyond conventional diameter-based 2D measurements, mint Lesion also supports volumetric assessments, tumor growth modeling, and the extraction of radiomics data during routine evaluations. Advanced DICOM annotation import and export capabilities (including NRRD, DICOM SR, and DICOM Segmentation Objects) help ensure data remains accessible for downstream AI and machine learning applications.
By integrating imaging findings into a digital patient model, mint Lesion generates structured radiology reports that capture evaluation results in a comprehensive and reproducible format. This provides clinicians and researchers with detailed information that can support treatment decisions and the validation of assessment methodologies.
With mint Lesion, no data is left behind, ensuring clinicians have the information they need to drive childhood cancer research forward. Join us in our mission to make a difference in the fight against childhood cancer.
